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1. Introduction
[Background] Segmental left ventricular (LV) wall systolic dysfunction has been considered
a significant sign of coronary artery disease (CAD) for many years. However, it is well
known that many heart diseases besides CAD cause abnormal LV wall motion. Therefore, it
is essential to verify that segmental LV wall systolic dysfunction is due to myocardial ische‐
mia. Although coronary angiography is typically used to determine the clinical significance
of CAD, it is also possible to visualize areas of ischemic myocardium noninvasively by echo‐
cardiography using microbubble contrast agents. Perfluorobutane microbubbles, consisting
of a hydrogenated egg-phosphatidylserine shell encapsulating perfluorobutane gas, offers
the advantage of resistance to destruction by ultrasound, thus enabling repeated scans per
injection.
[Methods] We used phase-inversion harmonic ultrasonography to assess the ability of per‐
fluorobutane microbubbles to detect ischemic myocardial areas due to coronary artery
stenosis in 66 patients who had undergone coronary angiography (CAG). Abnormal LV
wall motion was detected by longitudinal strain before CAG. Pre and post-injection images
were evaluated from late-diastolic points along the time-intensity curve.
[Results] The injection of perfluorobutane microbubbles caused a significant change in in‐
tensity in the left ventricular wall in the AP and SAX views in segments perfused by normal
coronary arteries (p<0.0001), but not in segments perfused by arteries with significant (≥
75%) stenosis. Receiver operating characteristic curve analysis showed that an intensity dif‐
© 2013 Kakihara; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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ference ≤ 6.3 dB in the AP view could detect ≥ 75% stenosis with a sensitivity of 98%, specif‐
icity of 94% and accuracy of 97%. An intensity difference ≤ 5.1 dB in the SAX view could
detect ≥ 75% stenosis with a sensitivity of 97%, specificity of 96% and accuracy of 97%.
[Conclusions] These data indicate that when optimal signal intensity difference parameters
have been accurately defined, perfluorobutane microbubbles can be used safely for highly
sensitive, specific and accurate visualization of ischemic myocardial areas due to coronary
artery stenosis.
2. Background
The ability to prevent, diagnosis and treat cardiac disease has improved over the last two
decades due to the remarkable and seemingly exponential advances in imaging technology
[1,2,3,4 ]. Ironically, the surprising increases in computing power and software design now
at the physician’s disposal have been greatly enhanced by the advent of a relatively uncom‐
plicated and a readily-synthesized molecule, the microbubble. Perfluorobutane microbub‐
bles consist of a macromolecular shell encapsulating a high molecular weight gas [5] and are
typically 1 to 10 µ in diameter. Their small size allows them to be introduced safely into the
circulatory system where they enhance ultrasonic wave scattering by blood, thereby provid‐
ing higher contrast to ultrasound images of the left ventricular myocardial wall. Ultrascan‐
ners operating at frequencies < 15 MHz oscillate the microbubbles, which results in
increased echo contrast. The vibrating microbubbles also emit harmonic signals that can
preferentially enhance the signal-to-noise ratio. In addition to their diagnostic advantages,
microbubbles also avoid the use of radiation and are generally more economical to use. Mi‐
crobubble ultrasound technology has been used to image other organs besides the heart (liv‐
er, pancreas, breast and kidney, in particular), and can be used to target drug-delivery
vehicles to different organs [6]. Basic biomedical researchers are also benefitting from micro‐
bubble reagents for delivering macromolecules, such as plasmid DNAs, into cells [7].
Two microbubble contrast agents for cardiac echocardiography, OPTISON™ and Defini‐
ty™, are approved for use in the United States, SonoVue™ is approved in Europe and Chi‐
na, and Levovist in Japan. But OPTISON™ and Definity™ are used for opacification of the
left ventricular cavity and endocardial border definition only. Levovist is used for myocar‐
dial contrast echocardiography (MCE). Safety problems occurred initially with each agent,
but continuing clinical studies overwhelmingly indicated their efficacy and safety [8,9].
More recently, contrast-enhanced ultrasound (CEUS) has been found safe for pediatric use
in subjects as young as two years old [10]. Furthermore, at the recent 16th European Symposi‐
um on Ultrasound Contrast Imaging in Rotterdam, Porter (USA) presented highly compelling
evidence that CEUS improved the prediction of patient outcomes when compared with nu‐
clear imaging or non-contrast ultrasound. He also pointed out that contrast imaging avoids
subjecting patients to the ionizing radiation inherent in nuclear techniques and suggested
that there was significant underutilization of CEUS.
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Because of these findings and our own clinical experience, we have persisted in our studies
on perfluorobutane microbubbles for coronary artery disease. However, at the present time,
this contrast agent has only been approved for hepatic diseases in Japan [11]. Here, we re‐
port our experience with the use of perfluorobutane microbubbles to perform MCE in 66 pa‐
tients who had undergone coronary angiography. Our data showed that perfluorobutane
microbubbles markedly and stably enhance visualization of ischemic myocardial areas due
to significant coronary artery stenosis and provided superior images compared with Levov‐
istTM, but with the caveat that imaging parameters require careful optimization.
3. Materials and Methods
3.1. Patients
Sixty-six patients with a history of coronary angiography (CAG) within the last three
months were enrolled in this study, and informed consent was obtained. The study was ap‐
proved by the clinic’s ethics committee. All procedures were performed in accordance with
The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experi‐
ments involving humans. The following aspects of the consent form were explained to the
patients: 1) the advantages, benefits, risks and possible side effects of the procedure to them
specifically as well as to patients with coronary artery disease in general, 2) the cost of the
procedure according to the regulations of the National Health Service, 3) the approximate
time of the procedure, and 4) the clinic staff and specialists that would be present during the
procedure. In addition, the approval of the ethics committee required that the procedure be
performed by a special team that included the following personnel: Dr. R. Kakihara since he
was in charge of the study, the nurses and echocardiographers who had experience with
MCE, at least one specialist in the use of SonazoidTM from Daiichi Sankyo Co. Ltd, and a me‐
chanical engineer and a technical specialist to operate the Vivid 7 Ultrasound System. All 24
patients enrolled had ≥ 75% significant coronary artery stenosis (significant stenosis).
Among them, single vessel disease was present in 11 patients, double vessel disease in 9 and
triple vessel disease in 4. No subject had a history of previous myocardial infarction. The fol‐
lowing patient data were obtained: age, 69.9±11.4 y/o; body weight, 60.5±12.1 kg; body sur‐
face area, 1.61±4.3 m²; blood pressure, 128.6±15.3/ 67.7±9.9 mmHg; heart rate, 65.3±9.0 beats/
min; LVEF (by angiography), 60.5±4.3%; LDL-cholesterol, 125.6±38.1 mg/dl; and triglyceride,
193.1±134.1 mg/dl. Six patients were treated for diabetes mellitus by oral medication and
their average HbA1c was 6.3±1.5%.
3.2. Instrumentation
Phase-inversion harmonic ultrasonography was performed using the Vivid 7 Dimension
digital ultrasound system, Version 7.0.3 (General Electric Healthcare, Inc., U.S.A.), and a
1.5/4.0 MHz active-matrix array (AMA) probe. The images were analyzed offline using
EchoPAC PC Version 108.1.4. Phase inversion harmonic sonography is two phase-inverted
but otherwise identical sonographic pulses are transmitted. Summing the returning echoes
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in a buffer cancels most of the fundamental and odd harmonic echoes and effectively ampli‐
fies the second harmonic. [12]
3.3. The first step
A longitudinal peak systolic strain map (LPSSM) has high diagnostic reliability to detect
segmental left ventricular wall abnormalities. [13,14] Thus, an LPSSM was created on any
patient with coronary artery disease (CAD) risk factors. When the LPSSM showed abnormal
left ventricular segmental wall systolic function, myocardial contrast echocardiography
(MCE) was done using Sonazoid™ to confirm whether the dysfunction was due to myocar‐
dial ischemia.
3.4. The second step
Materials: Sonazoid™ was obtained from Daiichi Sankyo Co. Ltd. (Tokyo, Japan).
Figure 1. Magnified reconstituted Sonazoid solution. A macromolecular shell is encapsulated by a high molecular
weight gas. The microbubbles are very weak and are destroyed easily by usual physical pressure and MI (mechanical
index). Sonazoid reconstituted in saline for injection of 2.5mL: Volume concentration: 6.9μL MB/mL Particle size:
2.3~2.9μm (median diameter) Involving gas: Perflubutane (C4F10) Membrane element: Hydrogenated egg phospha‐
tidyl serine (sodium) pH: 5.7~7.0 Osmotic pressure ratio: 0.9~1.1
Any remaining Sonazoid should be stored at room temperature and used within 2 hours.
Because SonazoidTM microbubbles are susceptible to destruction by physical pressure, 2.5 ml
were injected over at least 20 sec, not less than the systemic circulation time under the stress
of low dose ATP (0.15 mg/kg/min of Adenosine 5- Triphosphate Disodium) Figure 1, Figure
2, Figure 3, Figure 4.
Measurements: The echocardiographer was blinded to the results of CAG in the patients en‐
rolled. Three apex approach (AP) views and one parasternal short axis (SAX) view were re‐
corded per injection. The instrument settings were as follows: mechanical index (MI), 0.4-0.6
for the AP and 0.22 for the SAX views; frame rate, 21.2; and frequency, 1.5/3.0 MHz. These
were selected based on the recommendations of the specialist from Daiichi Sankyo Co. Ltd
who had experience with liver imaging. The MI was very low so as not to destroy the micro‐
bubbles but high enough to vibrate them. This vibration energy is necessary to create ultra‐
sonic cardiac images. The images taken were clear and of sufficient quality to be analyzed at
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these settings. The images were acquired from the time-intensity curve in late diastole just
before the P wave. Intensity differences before and after SonazoidTM injection were meas‐
ured at the same site. The intensity data were automatically shown on the upper right part
of the screen. We examined 3 AP views (APLAX: mid-anterior septum & mid-posterior seg‐
ment; AP2ch: mid-anterior and mid-inferior segment; AP4ch: mid lateral and mid-septal
segments) and mid-papillary muscle level SAX views (mid-anterior, mid-lateral, mid-poste‐
rior, mid-inferior, mid-septal a mid-anterior septal segments). The segments in the 3 AP
views that were perfused by coronary arteries with significant stenosis were designated as
Group A and the segments in the SAX views were designated as Group B. The segments in
the AP views that were perfused by normal or coronary arteries without significant stenosis
were designated as Group C and the segments in the SAX views were designated as Group
D. We compared the intensities of all four groups before and after Sonazoidinjection using a
paired t-test.
Figure 2. Process of making the Sonazoid reconstituted product. The “Chemoprotect spike” is inserted in the vial to
keep the pressure in the vial unchanged. Then, 2.5 ml of saline is drawn into the syringe. Then the needle is removed
and the syringe is connected to the luer part of the “Chemoprotect spike”.Then, 2.5 ml of saline is squeezed into the
vial through the “Chemoprotect spike”. The solution is shaken for one minute with the syringe attached. The reconsti‐
tuted Sonazoid is gathered once in the syringe, and then returned into the vial. To avoid decompression or pressuriza‐
tion in the syringe and vial, these procedures should be performed slowly.
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Figure 3. Chemoprotect Spike. This reconstituted Sonazoid production adjustment device consists of a main body, a
luer portion, filter housing, spike part, built in liquid filter for drug solution filtration, and an air filter for ventilation. a :
Cap, b : Luer portion, c : Spike (Main body), d : Protective cap, e : Protective cap, f : Filter housing, Fluid filter, Air filter
Figure 4. Method and route of injection of reconstituted Sonazoid. Sonazoid (2.5 ml) was injected slowly over 20 sec‐
onds. After finishing the injection of Sonazoid, saline (approximately 10 ml) was injected to flush the delivery route
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Figure 5. Longitudinal peak systolic strain map. This shows abnormal LV wall motion area, does not show ischemic





Figure 6. The picture of coronary arteries is superimposed on the strain map. By this method the relation between
coronary arteries and the area of abnormal LV wall motion is confirmed.
Figure 7. Sonazoid myocardial contrast echocardiography, APLAX views. The patient #7 (see Figure 3 for CAG images)
was examined before and after Sonazoid injection. The instrument was set to MI = 0.4. APLAX views before (A) and
after (B) Sonazoid. Intensity curves (C). Yellow, LV cavity; red, posterior wall (LCX area); and blue, interventricular sep‐
tum (LAD #6 area)
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Figure 8. Sonazoid myocardial contrast echocardiography, AP 2-chamber views. The instrument was set to MI = 0.4.
AP 2-chamber views before (A) and after (B) Sonazoid injection. Time-intensity curves (C). Yellow, LV cavity; red, inferi‐
or wall (RCA area); and blue, anterior wall (LAD area).
Figure 9. Sonazoid myocardial contrast echocardiography, AP-4 chamber views. The instrument was set to MI = 0.4.
AP 4 chamber views before (A) and after (B) Sonazoid injection. Time-intensity curves (C). Yellow, LV cavity; red, inter‐
ventricular septum (LAD #6 area); blue, lateral wall and apex (LAD #7 area).
What Should We Know About Prevented, Diagnostic, and Interventional Therapy in Coronary Artery Disease194
Figure 10. Sonazoid myocardial contrast echocardiography, SAX- pm views. The instrument was set to MI = 0.22.
SAXpm views before (A) and after (B, C) Sonzaoid injection. Time-intensity curves (D). Yellow, LV cavity; blue, anterior
wall; red, lateral wall (both are LAD #7 area); orange, posterior wall; green, inferior wall.
None  of  the  patients  experienced  adverse  affects  of  this  procedure.  Each  of  the  66  pa‐
tients enrolled in the study had undergone CAG and was diagnosed with significant cor‐
onary  artery  stenosis.  Patients  were  divided  into  four  groups  as  described  above,  and
myocardial segments perfused by the stenotic and normal vasculatures were examined by
ultrasonography before and after Sonazoid administration.  The data for one patient (#7)
are presented in Figures 5 through Figure 10.  Ultrasound images taken before and after
Sonazoid  administration  are  shown  in  6  Figures,  which  represent  the  strain  maps  and
APLAX, AP2ch, AP4ch and SAX-papillary muscle (pm) views, respectively. Figure 5 and
Figure 6 show the longitudinal peak systolic strain map and Figure 6 which is superim‐
posed coronary arteries on the map strongly implys this patient experienced no adverse
affect and had LAD single vessel disease. Figure 11 shows an angiogram of the left and
right coronary arteries.  In the left  panel,  the angiogram (left  coronary artery) clearly re‐
veals left anterior descending coronary artery stenosis obstructing 75% of the vessel’s nor‐
mal diameter. Stenotic regions are indicated by the arrows.In contrast, no involvement of
the right coronary artery could be discerned.
The data from 100 myocardial segments (16 patients) perfused by normal coronary arteries
and from 283 myocardial segments (50 patients) perfused by stenotic coronary arteries in 66
patients with coronary artery disease were grouped into A, B, C and D as designated above
and are summarized in Tables 1 and Table 2. Specifically, the intensity difference between
A-pre-injection (A-pre) and A–post-injection (A-post) was 1.3 ± 3.5 dB; the intensity differ‐
ence between B-pre and B-post was 0.9 ± 3.3 dB. The intensity differences in groups A and B
were not significant. For C-pre and C-post, the intensities were -33.4 ± 5.1 dB and -22.3 ± 6.8
A Noninvasive Alternative to Coronary Angiography: Myocardial Contrast Echocardiography Following Strain Map…
http://dx.doi.org/10.5772/45953
195
dB, respectively; and D-pre and D-post were -36.2 ± 4.8 dB and -22.6 ± 10.7 dB, respectively.
The intensity differences in groups C (14.1 ± 5.8 dB) and D (11.5 ± 4.3 dB) were both signifi‐
cant (p < 0.001). By ROC (receiver operating characteristic curve) analysis, intensity differen‐
ces ≤ 6.3 dB in the AP views could detect ≥ 75% stenosis with a sensitivity of 98%, specificity
of 94% and accuracy of 97%. An intensity difference ≤ 5.1 dB in the SAX view could detect ≥
75% stenosis with a sensitivity of 97%, specificity of 96% and accuracy of 97%. These data




A/AP 1.3 ± 3.5 dB (N.S.)
B/SAX 0.9 ± 3.3 dB (N.S)
Normal Groups
Group/View Intensity difference
C/AP 14.1 ± 5.8 dB (P < .001)
D/SAX 11.5 ± 4.3 dB (P < .001)
Table 1. Intensity differences before and after Sonazoid administration. A-pre-injection (A-pre) and –post-injection (A-
post): 1.3 ± 3.5 dB. B-pre and B-post: 0.9 ± 3.3 dB. The intensity differences for each pair were not significantly
different. C-pre and C-post: -33.4 ± 5.1 dB and -22.3 ± 6.8 dB; D-pre and D-post: -36.2 ± 4.8 dB and -22.6 ± 10.7 dB. The
differences between C (14.1 ± 5.8 dB) and D (11.5 ± 4.3 dB) were judged significant (P < 0.001)
Figure 11. Coronary artery angiography. Left: left coronary artery. Left anterior descending artery had 75% stenosis at
#7. Right: Right coronary artery was normal.
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View Sensitivity Specificity Accuracy
AP (Δ ≤ 6.3 dB) 0.98 0.94 0.97
SAXpm (Δ ≤ 5.1 dB) 0.97 0.96 0.97
Table 2. Sonazoid’s detection parameters for coronary artery stenosis. The optimal dB cut-off vales were selected that
gave the highest sensitivity and specificity. By ROC, intensity differences ≤ 6.3 dB in AP views detects ≥ 75% stenosis
with a sensitivity: 0.98, specificity: 0.94, accuracy: 0.97. In the SAX view an intensity difference ≤ 5.1 dB detects ≥ 75%
stenosis with a sensitivity: 0.97, specificity: 0.96, accuracy: 0.97.
The intraobserver reproducibility was determined by imaging the same patients after a four-
week interval and then calculating Cohen’s kappa (κ= 0.76, p < 0.001). To obtain the four-
week interval and then calculating Cohen’s kappa (κ= 0.76, p < 0.001). To obtain the
interobserver reproducibility, the same images were evaluated by another echocardiogra‐
pher who was employed at a different medical institute and had no knowledge of the proto‐
col. The interobserver reproducibility was excellent (κ= 0.98, p < 0.001). These two results
indicate that the reproducibly of Sonazoid MCE is sufficient for the use of this agent in the
clinical setting.
4. Discussion
Remarkable progress has been made over the last decade in medical imaging of the heart
and other organs. However, there is still an enormous worldwide mortality and morbidi‐
ty from coronary artery disease. A major hurdle in overcoming this situation is the inabil‐
ity to make a definite diagnosis of coronary artery stenosis or to screen coronary artery
disease easily and inexpensively.  Although myocardial ischemia it  thought to start  from
75% stenosis, patients usually have no symptoms with normal daily activities. When the
stenosis is ≥ 90%, patients may become symptomatic with normal daily activities. Present‐
ly, CAG is only one diagnostic method, but it is invasive and expensive. Routine preven‐
tative  cardiac  imaging  that  would  be  safe  (no  ionizing  radiation  or  allergenic  contrast
dyes), highly sensitive, specific and economical would obviously help mitigate this ongo‐
ing public health burden.
Echocardiography is one of the areas in which the most exciting advances have been made,
and it is especially attractive because it is becoming progressively more miniaturized and
can be used in a typical office setting rather than a dedicated imaging center. Current mo‐
dalities include real-time three-dimensional echocardiography, speckle tracking, contrast
echocardiography, intracardiac echocardiography and hand-held echocardiography.
Here, we show that Sonazoid can be successfully used in a local clinical setting and this con‐
trast agent allows the accurate detection of coronary artery stenosis ≥ 75%. This may be ac‐
counted for by Sonazoid’s resistance to acoustic pressure and its long half-life compared to
other microbubble-based contrast agents [15]. Our patients did not experience adverse ef‐
fects during or after the procedure. This is likely due to Sonazoid’s intrinsic nontoxicity, but
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also by the rapid metabolism of microbubbles via the respiratory system. We compared our
results with those of other studies [16, 17] and found similar accuracy for the detection of
significant (≥ 75%) coronary artery stenosis. Thus, our data argue for continued investiga‐
tions into its suitability for MCE and ultimate approval for this purpose, especially in view
of the limited number of microbubble-based contrast agents now available to cardiologists.
In future studies, it will be of great interest to determine whether Sonazoid is capable of de‐
tecting less significant degrees of stenosis.
5. Limitations
The limitations of this method are the same as the limitations of echocardiography. It is diffi‐
cult to obtain good B-mode images in patients with a thick subcutaneous fatty layer or em‐
physematous lung. The reliability of MCE to detect ischemia is clearly dependent on the
quality of the B-mode images. Another limitation is the process of making SonazoidTM since
the solution is somewhat complex compared with LevovistTM. In addition, the detection of
ischemic myocardial areas requires the ability to make and read time-intensity graphs.
However, we learned to overcome these limitations after four or five subjects.
6. Conclusions
This study showed that SonazoidTM has good clinical utility and better diagnostic accuracy
to detect significant coronary artery stenosis than other contrast agents. This is because the
concentration of SonazoidTM in circulating blood is more stable, and the agent has a longer
half-life than other contrast agents.
Comparisons between myocardial regions of affected and normal arteries in these patients
before and after SonazoidTM administration under low-dose ATP stress showed that MCE
could detect ≥75% stenosis with a sensitivity of 97%, specificity of 96% and accuracy of 97%.
An important factor in achieving these results was the optimization of the MI settings. We
believe that these data, taken together with patients not experiencing adverse effects during
or after the procedure, provide a compelling argument for extending these studies, with the
ultimate goal of providing cardiologists a powerful new tool for routine echocardiography.
The ability of this MCE method to identify various degrees of coronary artery stenosis needs
to be confirmed in larger, randomized trials. Although conventional echocardiography can‐
not detect the extent of myocardial tissue ischemia due to coronary artery stenosis, it can de‐
tect LV wall systolic dysfunction due to myocardial ischemia by strain mapping. By
applying these two methods, we could develop a new and more accurate diagnostic meth‐
od. The creation of an MCE map along with a strain map might be used to directly diagnose
the severity of coronary artery stenosis and extent of the ischemic myocardial area.
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Figure 12. The image of myocardial contrast echocardiography map (MCE Map: left) and the time-intensity curve of
the MCE of the patient by MCE MAP.
The extent of the ischemic myocardial area surely play a more leading and important role as
an index more than the severity of coronary artery stenosis to decide the indication of coro‐
nary artery intervention.
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